8027196b-a80b-4759-872d-b72c98905451
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 84
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.550
- MYC_TARGETS_V1+0.500
- G2M_CHECKPOINT+0.470
- OXIDATIVE_PHOSPHORYLATION+0.470
- DNA_REPAIR+0.350
- MTORC1_SIGNALING+0.350
- FATTY_ACID_METABOLISM+0.340
- TNFA_SIGNALING_VIA_NFKB+0.330
- MYC_TARGETS_V2+0.320
- UNFOLDED_PROTEIN_RESPONSE+0.260
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.500
- WNT_BETA_CATENIN_SIGNALING-0.420
- HEDGEHOG_SIGNALING-0.370
- ANGIOGENESIS-0.360
- MYOGENESIS-0.350
- APICAL_JUNCTION-0.270
- COAGULATION-0.260
- INTERFERON_ALPHA_RESPONSE-0.190
- APICAL_SURFACE-0.170
- UV_RESPONSE_DN-0.140
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | feccc57b-a987-4dd7-babf-1a8982bd64cc | — | — | 0.861 |
| 2 | SRR2932844 | — | — | 0.847 |
| 3 | 8824c0fd-764e-4525-952b-f25efa742772 | — | — | 0.832 |
| 4 | TCGA-IQ-A61G-01A-11R-A30B-07 | — | — | 0.806 |
| 5 | SRR26320071 | — | — | 0.798 |
| 6 | 17-020P2_Bladder | — | — | 0.795 |
| 7 | bf312cd5-e251-4d63-95b5-c379b3ef5ded | — | — | 0.790 |
| 8 | TCGA-AO-A0JD-01A-11R-A056-07 | — | C | 0.789 |
| 9 | SRR33532759 | — | E | 0.789 |
| 10 | be22f883.ee5e.4632.93d1.661ddc53608e | — | cohortA4 | 0.782 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 32 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.550 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.500 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.470 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.470 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.350 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.350 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.340 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.330 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.320 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.260 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.250 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.250 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.220 | Inavolisib | — uncovered |
| HYPOXIA | 0.200 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.200 | Idelalisib | — uncovered |
| PEROXISOME | 0.190 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.180 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.180 | Remibrutinib | — uncovered |
| HEME_METABOLISM | 0.140 | Temsirolimus | — uncovered |
| ALLOGRAFT_REJECTION | 0.130 | Idelalisib | — uncovered |